786 related articles for article (PubMed ID: 26308779)
21. The efficacy and safety of reduced-dose sulfamethoxazole-trimethoprim for chemoprophylaxis of
Harada T; Kato R; Sueda Y; Funaki Y; Takata M; Okazaki R; Hasegawa Y; Yamasaki A
Mod Rheumatol; 2021 May; 31(3):629-635. PubMed ID: 32820678
[TBL] [Abstract][Full Text] [Related]
22. Prevention of Pneumocystis carinii pneumonia in cardiac transplant recipients by trimethoprim sulfamethoxazole.
Olsen SL; Renlund DG; O'Connell JB; Taylor DO; Lassetter JE; Eastburn TE; Hammond EH; Bristow MR
Transplantation; 1993 Aug; 56(2):359-62. PubMed ID: 8356591
[TBL] [Abstract][Full Text] [Related]
23. Pneumocystis pneumonia in solid organ transplant recipients: not yet an infection of the past.
Wang EH; Partovi N; Levy RD; Shapiro RJ; Yoshida EM; Greanya ED
Transpl Infect Dis; 2012 Oct; 14(5):519-25. PubMed ID: 22571389
[TBL] [Abstract][Full Text] [Related]
24. Effectiveness and safety of lower dose sulfamethoxazole/trimethoprim therapy for Pneumocystis jirovecii pneumonia in patients with systemic rheumatic diseases: A retrospective multicenter study.
Ohmura SI; Naniwa T; Tamechika SY; Miyamoto T; Shichi D; Kazawa N; Iwagaitsu S; Maeda S; Wada JI; Niimi A
J Infect Chemother; 2019 Apr; 25(4):253-261. PubMed ID: 30642768
[TBL] [Abstract][Full Text] [Related]
25. Twice weekly prophylaxis with trimethoprim/sulfamethoxazole for
Awad M; Sierra CM; Mesghali E; Bahjri K
J Oncol Pharm Pract; 2021 Dec; 27(8):1936-1939. PubMed ID: 33307970
[TBL] [Abstract][Full Text] [Related]
26. Risk factors for Pneumocystis jirovecii pneumonia in kidney transplant recipients and appraisal of strategies for selective use of chemoprophylaxis.
de Boer MG; Kroon FP; le Cessie S; de Fijter JW; van Dissel JT
Transpl Infect Dis; 2011 Dec; 13(6):559-69. PubMed ID: 21689251
[TBL] [Abstract][Full Text] [Related]
27. Prophylactic effect of low-dose trimethoprim-sulfamethoxazole for Pneumocystis jirovecii pneumonia in adult recipients of kidney transplantation: a real-world data study.
Chen RY; Li DW; Wang JY; Zhuang SY; Wu HY; Wu JJ; Qu JW; Sun N; Zhong C; Zhu C; Zhang M; Yu YT; Yuan XD
Int J Infect Dis; 2022 Dec; 125():209-215. PubMed ID: 36243280
[TBL] [Abstract][Full Text] [Related]
28. Retrospective review of intravenous pentamidine for Pneumocystis pneumonia prophylaxis in allogeneic hematopoietic stem cell transplantation.
Diri R; Anwer F; Yeager A; Krishnadasan R; McBride A
Transpl Infect Dis; 2016 Feb; 18(1):63-9. PubMed ID: 26606757
[TBL] [Abstract][Full Text] [Related]
29. Comparative efficacy and safety of Pneumocystis jirovecii pneumonia prophylaxis regimens for people living with HIV: a systematic review and network meta-analysis of randomized controlled trials.
Prosty C; Katergi K; Sorin M; Rjeily MB; Butler-Laporte G; McDonald EG; Lee TC
Clin Microbiol Infect; 2024 Jul; 30(7):866-876. PubMed ID: 38583518
[TBL] [Abstract][Full Text] [Related]
30. Pneumocystis pneumonia in patients with rheumatic diseases receiving prolonged, non-high-dose steroids-clinical implication of primary prophylaxis using trimethoprim-sulfamethoxazole.
Park JW; Curtis JR; Kim MJ; Lee H; Song YW; Lee EB
Arthritis Res Ther; 2019 Sep; 21(1):207. PubMed ID: 31521185
[TBL] [Abstract][Full Text] [Related]
31. Treatment of Pneumocystis pneumonia with intermediate-dose and step-down to low-dose trimethoprim-sulfamethoxazole: lessons from an observational cohort study.
Creemers-Schild D; Kroon FP; Kuijper EJ; de Boer MG
Infection; 2016 Jun; 44(3):291-9. PubMed ID: 26471512
[TBL] [Abstract][Full Text] [Related]
32. Dapsone safety in hematology patients: Pathways to optimizing Pneumocystis jirovecii pneumonia prophylaxis in hematology malignancy and transplant recipients.
Urbancic KF; Pisasale D; Wight J; Trubiano JA
Transpl Infect Dis; 2018 Dec; 20(6):e12968. PubMed ID: 30030892
[TBL] [Abstract][Full Text] [Related]
33. Conventional-dose Versus Half-dose Sulfamethoxazole-trimethoprim for the Prophylaxis of Pneumocystis Pneumonia in Patients with Systemic Rheumatic Disease: A Non-blind, Randomized Controlled Trial.
Abe Y; Fujibayashi K; Nishizaki Y; Yanagisawa N; Nojiri S; Nakano S; Tada K; Yamaji K; Tamura N
Acta Med Okayama; 2019 Feb; 73(1):85-89. PubMed ID: 30820060
[TBL] [Abstract][Full Text] [Related]
34. Pneumocystis jirovecii pneumonia prophylaxis in allogeneic hematopoietic cell transplant recipients: can we always follow the guidelines?
Redjoul R; Robin C; Foulet F; Leclerc M; Beckerich F; Cabanne L; di Blasi R; Pautas C; Toma A; Botterel F; Maury S; Cordonnier C
Bone Marrow Transplant; 2019 Jul; 54(7):1082-1088. PubMed ID: 30413810
[TBL] [Abstract][Full Text] [Related]
35. Pneumocystis jirovecii pneumonia in kidney transplantation.
Goto N; Oka S
Transpl Infect Dis; 2011 Dec; 13(6):551-8. PubMed ID: 22093172
[TBL] [Abstract][Full Text] [Related]
36. Pneumocystis jirovecii pneumonia is rare in renal transplant recipients receiving only one month of prophylaxis.
Anand S; Samaniego M; Kaul DR
Transpl Infect Dis; 2011 Dec; 13(6):570-4. PubMed ID: 22093215
[TBL] [Abstract][Full Text] [Related]
37. Clindamycin-primaquine for pneumocystis jiroveci pneumonia in renal transplant patients.
Nickel P; Schürmann M; Albrecht H; Schindler R; Budde K; Westhoff T; Millward J; Suttorp N; Reinke P; Schürmann D
Infection; 2014 Dec; 42(6):981-9. PubMed ID: 25168263
[TBL] [Abstract][Full Text] [Related]
38. Alternative pneumocystis prophylaxis in solid organ transplant recipients at two large transplant centers.
Lum J; Echenique I; Athans V; Koval CE
Transpl Infect Dis; 2021 Feb; 23(1):e13461. PubMed ID: 32894607
[TBL] [Abstract][Full Text] [Related]
39. Benefits of sulfamethoxazole-trimethoprim prophylaxis on rates of sepsis after kidney transplant.
Horwedel TA; Bowman LJ; Saab G; Brennan DC
Transpl Infect Dis; 2014 Apr; 16(2):261-9. PubMed ID: 24621104
[TBL] [Abstract][Full Text] [Related]
40. Treatment of Pneumocystis carinii pneumonia in patients with AIDS.
Wordell CJ; Hauptman SP
Clin Pharm; 1988 Jul; 7(7):514-27. PubMed ID: 3138063
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
